FAEGX | VIGAX | FAEGX / VIGAX | |
Total Expense Ratio | 1.17 | 0.05 | 2,340% |
Annual Report Gross Expense Ratio | 1.17 | 0.05 | 2,340% |
Fund Existence | 33 years | 25 years | - |
Gain YTD | 9.756 | 12.589 | 77% |
Front Load | 4% | N/A | - |
Min. Initial Investment | 0 | 3000 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 12.7B | 324B | 4% |
Annual Yield % from dividends | 0.00 | 0.43 | - |
Returns for 1 year | 3.24 | 24.02 | 13% |
Returns for 3 years | 41.59 | 73.68 | 56% |
Returns for 5 years | 38.37 | 107.21 | 36% |
Returns for 10 years | 109.85 | 321.60 | 34% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
THNR | 22.94 | 0.39 | +1.74% |
Amplify Weight Loss Drug & Treatment ETF | |||
DAX | 45.38 | 0.08 | +0.17% |
Global X DAX Germany ETF | |||
GLV | 5.77 | 0.01 | +0.12% |
Clough Global Dividend and Income Fund | |||
TCHP | 47.55 | -0.11 | -0.23% |
T. Rowe Price Blue Chip Growth ETF | |||
SIMS | 38.35 | -0.60 | -1.53% |
SPDR® S&P Kensho Intelligent Strctr ETF |